Tourette's syndrome has proved a tough nut to crack pharmacologically but a couple of biotechs – Sweden's Asarina Pharma and Emalex Biosciences Inc. in the US – are advancing promising candidates that could soon enter late-stage trials.
Asarina And Emalex Carry The Torch For Tourette's
Alternatives To Antipsychotics Are Advancing
The pipeline to treat the neurological disorder, which is characterized by uncontrolled rapid and repeated movements or sounds, is very thin but a couple of biotechs either side of the Atlantic are making progress.
More from Neurological
More from Therapy Areas
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.